ArticleMolecular therapy : the journal of the American Society of Gene Therapy2015
Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Cytotoxic CD4Signal transduction and targeted therapy · 2026Review
- B7-H3-Targeting Chimeric Antigen Receptors Epstein-Barr Virus-specific T Cells Provides a Tumor Agnostic Off-The-Shelf Therapy Against B7-H3-positive Solid Tumors.Cancer research communications · 2024Article
- Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells.Molecular therapy. Methods & clinical development · 2024Article
- Virus-Specific T-Cell Therapy for Viral Infections of the Central Nervous System: A Review.Viruses · 2023Review
- Article
- Review
- Harnessing T Cells to Control Infections After Allogeneic Hematopoietic Stem Cell Transplantation.Frontiers in immunology · 2020Review
- Management of PTLD After Hematopoietic Stem Cell Transplantation: Immunological Perspectives.Frontiers in immunology · 2020Review
- Article
- Donor Allospecific CD44Frontiers in immunology · 2019Article
- Role of Epstein-Barr Virus in the Pathogenesis of Head and Neck Cancers and Its Potential as an Immunotherapeutic Target.Frontiers in oncology · 2018Review
- Improving the safety of T-Cell therapies using an inducible caspase-9 gene.Experimental hematology · 2016Review
- Chimeric antigen receptors: driving immunology towards synthetic biology.Current opinion in immunology · 2016Review
- Review
- Prophylactic and therapeutic adenoviral vector-based multivirus-specific T-cell immunotherapy for transplant patients.Molecular therapy. Methods & clinical development · 2016Article
- Modern approaches to HLA-haploidentical blood or marrow transplantation.Nature reviews. Clinical oncology · 2016Review
- Broad spectrum antiviral T cells for viral complications after hematopoietic stem cell transplantation.Annals of translational medicine · 2015Article
- CMV-specific T cells generated from naïve T cells recognize atypical epitopes and may be protective in vivo.Science translational medicine · 2015Article
- The coming of age of adoptive T-cell therapy for viral infection after stem cell transplantation.Annals of translational medicine · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
Abstract
A 12-year-old boy with refractory acute lymphoblastic leukemia received a haploidentical transplant from his mother. As prophylaxis for Epstein-Barr virus (EBV), cytomegalovirus (CMV) and adenovirus, he received ex vivo expanded virus-specific donor T cells 3.5 months after transplant. Four weeks later leukemic blasts bearing the E2A deletion, identified by fluorescent in situ hybridization (FISH), appeared transiently in the blood followed by a FISH-negative hematological remission, which was sustained until a testicular relapse 3.5 months later. Clearance of the circulating leukemic cells coincided with a marked increase in circulating virus-specific T cells. The virus-specific cytotoxic T-cell (CTL) line showed strong polyfunctional reactivity with the patient's leukemic cells but not phytohemagglutinin (PHA) blasts, suggesting that virus-specific CTL lines may have clinically significant antileukemia activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.